These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17540164)

  • 1. Stopping ras in its tracks.
    Der CJ; Van Dyke T
    Cell; 2007 Jun; 129(5):855-7. PubMed ID: 17540164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
    Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.
    Gupta S; Ramjaun AR; Haiko P; Wang Y; Warne PH; Nicke B; Nye E; Stamp G; Alitalo K; Downward J
    Cell; 2007 Jun; 129(5):957-68. PubMed ID: 17540175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3 kinases in cancer: from oncogene artifact to leading cancer target.
    Zhao JJ; Roberts TM
    Sci STKE; 2006 Dec; 2006(365):pe52. PubMed ID: 17164467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visualization of Ras-PI3K interaction in the endosome using BiFC.
    Tsutsumi K; Fujioka Y; Tsuda M; Kawaguchi H; Ohba Y
    Cell Signal; 2009 Nov; 21(11):1672-9. PubMed ID: 19616621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAS and PI3K in lung cancer.
    Downward J
    Nat Med; 2008 Dec; 14(12):1315-6. PubMed ID: 19057554
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical target promiscuity: lessons from ras molecular trials.
    Rengan R; Cengel KA; Hahn SM
    Cancer Metastasis Rev; 2008 Sep; 27(3):403-14. PubMed ID: 18461427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
    Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
    Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway.
    Ram R; Uziel O; Eldan O; Fenig E; Beery E; Lichtenberg S; Nordenberg Y; Lahav M
    Clin Cancer Res; 2009 Feb; 15(3):914-23. PubMed ID: 19188162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways.
    Wang J; Yuan Y; Zhou Y; Guo L; Zhang L; Kuai X; Deng B; Pan Z; Li D; He F
    J Proteome Res; 2008 Sep; 7(9):3879-89. PubMed ID: 18624398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transduction. Prelude to an anniversary for the RAS oncogene.
    Downward J
    Science; 2006 Oct; 314(5798):433-4. PubMed ID: 17053139
    [No Abstract]   [Full Text] [Related]  

  • 12. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling.
    Lee SG; Su ZZ; Emdad L; Sarkar D; Franke TF; Fisher PB
    Oncogene; 2008 Feb; 27(8):1114-21. PubMed ID: 17704808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct functions of H-Ras and K-Ras in proliferation and survival of primary hepatocytes due to selective activation of ERK and PI3K.
    Rosseland CM; Wierød L; Flinder LI; Oksvold MP; Skarpen E; Huitfeldt HS
    J Cell Physiol; 2008 Jun; 215(3):818-26. PubMed ID: 18163378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation.
    Wells V; Downward J; Mallucci L
    Oncogene; 2007 Dec; 26(55):7709-14. PubMed ID: 17603562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RalGDS comes of age.
    Rodriguez-Viciana P; McCormick F
    Cancer Cell; 2005 Mar; 7(3):205-6. PubMed ID: 15766656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
    Menges CW; McCance DJ
    Oncogene; 2008 May; 27(20):2934-40. PubMed ID: 18059341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS: target for cancer therapy.
    Saxena N; Lahiri SS; Hambarde S; Tripathi RP
    Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
    Xu J; Ismat FA; Wang T; Yang J; Epstein JA
    Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.